428 related articles for article (PubMed ID: 30269082)
1. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer.
Wang DS; Liu ZX; Lu YX; Bao H; Wu X; Zeng ZL; Liu Z; Zhao Q; He CY; Lu JH; Wang ZQ; Qiu MZ; Wang F; Wang FH; Li YH; Wang XN; Xie D; Jia WH; Shao YW; Xu RH
Gut; 2019 Jul; 68(7):1152-1161. PubMed ID: 30269082
[TBL] [Abstract][Full Text] [Related]
2. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.
Chen Z; Sun T; Yang Z; Zheng Y; Yu R; Wu X; Yan J; Shao YW; Shao X; Cao W; Wang X
Mol Genet Genomic Med; 2020 Feb; 8(2):e1079. PubMed ID: 31867841
[TBL] [Abstract][Full Text] [Related]
3. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer.
Wang H; Li B; Liu Z; Gong J; Shao L; Ren J; Niu Y; Bo S; Li Z; Lai Y; Lu S; Gao J; Shen L
Eur J Cancer; 2018 Jan; 88():92-100. PubMed ID: 29207318
[TBL] [Abstract][Full Text] [Related]
4. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
Saeki H; Oki E; Kashiwada T; Arigami T; Makiyama A; Iwatsuki M; Narita Y; Satake H; Matsuda Y; Sonoda H; Shimokawa M; Maehara Y;
Eur J Cancer; 2018 Dec; 105():41-49. PubMed ID: 30391779
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.
Pietrantonio F; Fucà G; Morano F; Gloghini A; Corso S; Aprile G; Perrone F; De Vita F; Tamborini E; Tomasello G; Gualeni AV; Ongaro E; Busico A; Giommoni E; Volpi CC; Laterza MM; Corallo S; Prisciandaro M; Antista M; Pellegrinelli A; Castagnoli L; Pupa SM; Pruneri G; de Braud F; Giordano S; Cremolini C; Di Bartolomeo M
Clin Cancer Res; 2018 Mar; 24(5):1082-1089. PubMed ID: 29208673
[No Abstract] [Full Text] [Related]
6. Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer.
Wang Y; Zhao C; Chang L; Jia R; Liu R; Zhang Y; Gao X; Li J; Chen R; Xia X; Bulbul A; Husain H; Guan Y; Yi X; Xu J
EBioMedicine; 2019 May; 43():261-269. PubMed ID: 31031019
[TBL] [Abstract][Full Text] [Related]
7. Tracking of trastuzumab resistance in patients with HER2-positive metastatic gastric cancer by CTC liquid biopsy.
Zhang J; Qiu W; Zhang W; Chen Y; Shen H; Zhu H; Liang X; Shen Z
Am J Cancer Res; 2023; 13(11):5684-5697. PubMed ID: 38058840
[TBL] [Abstract][Full Text] [Related]
8. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
9. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
[TBL] [Abstract][Full Text] [Related]
10. HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study.
Haffner I; Schierle K; Raimúndez E; Geier B; Maier D; Hasenauer J; Luber B; Walch A; Kolbe K; Riera Knorrenschild J; Kretzschmar A; Rau B; Fischer von Weikersthal L; Ahlborn M; Siegler G; Fuxius S; Decker T; Wittekind C; Lordick F
J Clin Oncol; 2021 May; 39(13):1468-1478. PubMed ID: 33764808
[TBL] [Abstract][Full Text] [Related]
11. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
Roviello G; Aprile G; D'Angelo A; Iannone LF; Roviello F; Polom K; Mini E; Catalano M
Gastric Cancer; 2021 Jul; 24(4):765-779. PubMed ID: 33742317
[TBL] [Abstract][Full Text] [Related]
12. Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.
Takahashi N; Furuta K; Taniguchi H; Sasaki Y; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Hamaguchi T; Shimada Y; Yamada Y
Oncotarget; 2016 Jan; 7(4):4925-38. PubMed ID: 26716644
[TBL] [Abstract][Full Text] [Related]
13. Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer.
Ye Q; Qi F; Bian L; Zhang SH; Wang T; Jiang ZF
Chin Med J (Engl); 2017 Mar; 130(5):522-529. PubMed ID: 28229982
[TBL] [Abstract][Full Text] [Related]
14. HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.
Sakai H; Tsurutani J; Iwasa T; Komoike Y; Sakai K; Nishio K; Nakagawa K
Breast Cancer; 2018 Sep; 25(5):605-613. PubMed ID: 29700710
[TBL] [Abstract][Full Text] [Related]
15. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
Kotoula V; Tsakiri K; Koliou GA; Lazaridis G; Papadopoulou K; Giannoulatou E; Tikas I; Christodoulou C; Chatzopoulos K; Bobos M; Pentheroudakis G; Tsolaki E; Batistatou A; Kotsakis A; Koutras A; Linardou H; Razis E; Res E; Pectasides D; Fountzilas G
Clin Breast Cancer; 2019 Apr; 19(2):113-125.e4. PubMed ID: 30545790
[TBL] [Abstract][Full Text] [Related]
16. The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.
Janiszewska M; Stein S; Metzger Filho O; Eng J; Kingston NL; Harper NW; Rye IH; Alečković M; Trinh A; Murphy KC; Marangoni E; Cristea S; Oakes B; Winer EP; Krop IE; Russnes HG; Spellman PT; Bucher E; Hu Z; Chin K; Gray JW; Michor F; Polyak K
JCI Insight; 2021 Jun; 6(11):. PubMed ID: 33886505
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
Porth I; Hirsch D; Ceribas Y; Weidner P; Weichert W; Götze TO; Perner S; Luley K; Heyer CM; de la Torre C; Hofheinz RD; Lorenzen S; Gaiser T
Eur J Cancer; 2023 Apr; 183():119-130. PubMed ID: 36848831
[TBL] [Abstract][Full Text] [Related]
18. Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2-positive advanced gastric cancer.
Kunzke T; Hölzl FT; Prade VM; Buck A; Huber K; Feuchtinger A; Ebert K; Zwingenberger G; Geffers R; Hauck SM; Haffner I; Luber B; Lordick F; Walch A
Clin Transl Med; 2021 Sep; 11(9):e547. PubMed ID: 34586736
[No Abstract] [Full Text] [Related]
19. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
Mezynski MJ; Farrelly AM; Cremona M; Carr A; Morgan C; Workman J; Armstrong P; McAuley J; Madden S; Fay J; Sheehan KM; Kay EW; Holohan C; Elamin Y; Rafee S; Morris PG; Breathnach O; Grogan L; Hennessy BT; Toomey S
J Transl Med; 2021 May; 19(1):184. PubMed ID: 33933113
[TBL] [Abstract][Full Text] [Related]
20. Characterization of PI3KCA and BRAF mutations in gastric adenocarcinoma: An approach to a personalized targeted therapy for Moroccan HER2 overexpressed patients.
Joutei HAH; Marchoudi N; Mahfoud W; Sadaoui I; Fechtali T; Benomar H
Arab J Gastroenterol; 2018 Dec; 19(4):155-158. PubMed ID: 30503528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
